181 related articles for article (PubMed ID: 15379725)
21. Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model.
Tanaka K; Towata S; Nakao K; Mizuguchi H; Hayakawa T; Niwa M; Ishii N; Nagayama Y
Clin Endocrinol (Oxf); 2003 Dec; 59(6):734-42. PubMed ID: 14974915
[TBL] [Abstract][Full Text] [Related]
22. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
Spitzweg C; Baker CH; Bergert ER; O'Connor MK; Morris JC
Hum Gene Ther; 2007 Oct; 18(10):916-24. PubMed ID: 17931047
[TBL] [Abstract][Full Text] [Related]
23. Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor.
Adachi Y; Matsubara S; Muramatsu T; Curiel DT; Reynolds PN
J Pediatr Surg; 2002 Apr; 37(4):588-92. PubMed ID: 11912516
[TBL] [Abstract][Full Text] [Related]
24. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
25. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
26. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.
Drosten M; Stiewe T; Pützer BM
Hum Gene Ther; 2003 Jul; 14(10):971-82. PubMed ID: 12869215
[TBL] [Abstract][Full Text] [Related]
27. Tissue-targeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems.
Kobayashi M; Okada T; Murakami T; Ozawa K; Kobayashi E; Morita T
Urology; 2007 Dec; 70(6):1230-6. PubMed ID: 18158067
[TBL] [Abstract][Full Text] [Related]
28. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
29. A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant.
Drosten M; Frilling A; Stiewe T; Pützer BM
Surgery; 2002 Dec; 132(6):991-7; discussion 997. PubMed ID: 12490846
[TBL] [Abstract][Full Text] [Related]
30. Adenoviral infection of thyroid cells: a rationale for gene therapy for metastatic thyroid carcinoma.
Zeiger MA; Takiyama Y; Bishop JO; Ellison AR; Saji M; Levine MA
Surgery; 1996 Dec; 120(6):921-5. PubMed ID: 8957474
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase.
Barzon L; Bonaguro R; Castagliuolo I; Chilosi M; Franchin E; Del Vecchio C; Giaretta I; Boscaro M; Palù G
Eur J Endocrinol; 2003 Jan; 148(1):73-80. PubMed ID: 12534360
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer.
Anderson LM; Swaminathan S; Zackon I; Tajuddin AK; Thimmapaya B; Weitzman SA
Gene Ther; 1999 May; 6(5):854-64. PubMed ID: 10505111
[TBL] [Abstract][Full Text] [Related]
33. Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene.
Zhang R; Baunoch D; DeGroot LJ
Thyroid; 1998 Dec; 8(12):1137-46. PubMed ID: 9920370
[TBL] [Abstract][Full Text] [Related]
34. Radioiodine therapy of thyroid carcinoma following Pax-8 gene transfer.
Mu D; Huang R; Ma X; Li S; Kuang A
Gene Ther; 2012 Apr; 19(4):435-42. PubMed ID: 21833035
[TBL] [Abstract][Full Text] [Related]
35. Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells.
Jacob D; Schumacher G; Bahra M; Davis J; Zhu HB; Zhang LD; Teraishi F; Neuhaus P; Fang BL
World J Gastroenterol; 2005 May; 11(17):2552-6. PubMed ID: 15849810
[TBL] [Abstract][Full Text] [Related]
36. Head and neck cancer: gene therapy approaches. Part 1: adenoviral vectors.
Nemunaitis J; O'Brien J
Expert Opin Biol Ther; 2002 Feb; 2(2):177-85. PubMed ID: 11849117
[TBL] [Abstract][Full Text] [Related]
37. Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.
Xiong Z; Cheng Z; Zhang X; Patel M; Wu JC; Gambhir SS; Chen X
J Nucl Med; 2006 Jan; 47(1):130-9. PubMed ID: 16391197
[TBL] [Abstract][Full Text] [Related]
38. Construction of a novel oncolytic adenoviral vector and its biological characteristics.
Zhang M; Zhang X; Han Z; Chen X; Yang L; Sheng Y; Wen J
Oncol Rep; 2013 Feb; 29(2):798-804. PubMed ID: 23165979
[TBL] [Abstract][Full Text] [Related]
39. Adenovirus HSV-TK construct with thyroid-specific promoter: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway.
Kitazono M; Chuman Y; Aikou T; Fojo T
Int J Cancer; 2002 May; 99(3):453-9. PubMed ID: 11992417
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system.
Stoff-Khalili MA; Stoff A; Rivera AA; Banerjee NS; Everts M; Young S; Siegal GP; Richter DF; Wang M; Dall P; Mathis JM; Zhu ZB; Curiel DT
Breast Cancer Res; 2005; 7(6):R1141-52. PubMed ID: 16457694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
